Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 7/20 | 0.58 |
| ▸ | CDK8 | P49336 | 2/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | WRN | Q14191 | 1/20 | 0.54 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | FLT4 | P35916 | 1/20 | 0.53 |
| ▸ | FRK | P42685 | 1/20 | 0.53 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.53 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.53 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.53 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282364 | 0.83 | MAPT (0.59) | KDRTRPV1BAZ1A | |
| SCHEMBL281864 | 0.83 | KDR (0.85) | KDRCDK8TRPV1 | |
| SCHEMBL1904289 | 0.80 | AR (0.64) | ARKDRCDK8BLMWRN | |
| SCHEMBL7174280 | 0.80 | AR (0.60) | ARKDRCDK8BLMWRN | |
| SCHEMBL6586572 | 0.80 | TRPV1 (0.64) | ARKDRCDK8TRPV1BLM | |
| SCHEMBL1903846 | 0.79 | AR (0.63) | ARKDRCDK8BLMWRN | |
| SCHEMBL8530877 | 0.79 | AR (0.58) | ARKDRCDK8BLMWRN | |
| SCHEMBL31356647 | 0.79 | AR (0.58) | ARKDRCDK8BLMWRN | |
| SCHEMBL20560568 | 0.79 | GRM4 (0.61) | ARKDRCDK8BLMWRN | |
| SCHEMBL1380778 | 0.79 | AR (0.58) | ARKDRCDK8BLMWRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590941-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-3590941-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2021-04-20 | — | — | US | disclosed |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2021-04-20 | — | — | US | disclosed |
| CN-108530455-B | Urea substituted aromatic ring connecting dioxane and quinazoline compound or medicinal salt or hydrate and application as tyrosine kinase inhibitor | 北京赛特明强医药科技有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20200061065-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2020-02-27 | — | — | US | disclosed |
| US-20200061065-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2020-02-27 | — | — | US | disclosed |
| CN-108530455-A | Aromatic ring Lian dioxanes simultaneously quinazoline compounds or pharmaceutical salts or hydrate and the application as tyrosine kinase inhibitor of urea substitution | 北京赛特明强医药科技有限公司 | 2018-09-14 | — | — | CN | disclosed |
| US-8957087-B2 | Heterocyclic substituted acardite derivate and application thereof | Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) | 2015-02-17 | — | — | US | disclosed |
| EP-2428506-B1 | HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF | NANJING LUYESIKE PHARMACEUTICAL CO LTD (CN) | 2014-03-05 | — | — | EP | disclosed |
| EP-2428506-A1 | HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF | Jiangsu Provincial Institute Of Materia Medica Co. (CN) | 2012-03-14 | — | — | EP | disclosed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061065-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BRAF, RAF1, ARAF | AR 2964/4885KDR 5/4885CDK8 137/4885 |
| US-10980809-B2 | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | BRAF, RAF1, ARAF | AR 2964/4885KDR 5/4885CDK8 137/4885 |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 | AR 2020/4885KDR 3633/4885CDK8 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.